Claim 20% Off Global Market Reports With Code ONLINE20 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Is The Present And Forecasted Size Of The Bevacizumab Biosimilars Market?

The market size for bevacizumab biosimilars has experienced robust growth in the past years. It is predicted to escalate from a value of $1.53 billion in 2024 to reach $1.64 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.2%. Factors such as patent expiry, efforts to control healthcare costs, rising occurrences of cancer, market competitiveness, patient accessibility and affordability, as well as the acceptance of biosimilars, have been influential in shaping growth during the historic period.

In the coming years, the bevacizumab biosimilars market is projected to experience robust growth. The market is anticipated to expand to a worth of “$2.23 billion by 2029, with a compound annual growth rate (CAGR) of 7.9%. Factors contributing to this growth during the forecast period include increased demand for treatments for cancer, skills in biosimilar development, pressures within the healthcare system, regulatory landscapes for biosimilars, and biosimilar interchangeability. Key trends expected in the forecast period encompass collaborations and partnerships, advancements and approvals in regulations, development and innovation of biosimilars, strategies for market access, and lifecycle management of biosimilars.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10848&type=smp

Which Factors Are Steering Growth In The Bevacizumab Biosimilars Market?

The escalating number of cancer cases is anticipated to fuel the expansion of the bevacizumab biosimilar market. The term “cancer incidence” relates to the total new cancer cases identified within a certain population over a specific time frame. Bevacizumab is a biological product that suppresses tumor angiogenesis, potentially leading to tumor reduction and growth deterrence. Its efficacy and safety are akin to those of reference biologic products when used to treat patients with advanced non-small cell lung cancer or metastatic colorectal cancer. For example, in October 2024, the UK’s National Health Service (NHS) announced 346,217 new cancer cases in 2022, equating to an average of 948 cases daily. This is a 5% increase when compared to the 329,664 cases diagnosed in 2021. There was also a 7% increase in cancer diagnoses, rising from 167,917 to 180,877 in 2022. As such, the escalating occurrence of cancer is what drives the market for bevacizumab biosimilars.

How Is The Global Bevacizumab Biosimilars Market Broken Down By Segment?

The bevacizumab biosimilars market covered in this report is segmented –

1) By Product: Avastin, Mvasi, Zirabev, Aybintio, Other Products

2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels

3) By Application: Colorectal Cancer, Non-small Cell Lung Cancer, Glioblastoma, Renal Cell Carcinoma, Cervical Cancer, Ovarian Cancer

Subsegments:

1) By Avastin: Original Avastin Product

2) By Mvasi: Mvasi (Amgen Biosimilar)

3) By Zirabev: Zirabev (Pfizer Biosimilar)

4) By Aybintio: Aybintio (Samsung Bioepis Biosimilar)

5) By Other Products: Additional Bevacizumab Biosimilars

Which Trends Are Likely To Redefine Growth Paths In The Bevacizumab Biosimilars Market?

The bevacizumab biosimilars market is witnessing a significant trend of product innovation. Market leaders are focusing on the development of innovative products to enhance their market dominance. Viatris and Biocon Biologics, both US-based pharmaceutical firms, exemplified this trend when they introduced a new biosimilar named Abevmy (bevacizumab), mirroring Roche’s Avastin (bevacizumab), in May 2022. Health Canada has approved Abevmy for use in four oncology areas. Like the original biologic, this product guarantees efficacy, safety, and quality, being a synthetically produced humanized monoclonal antibody (MA) that neutralizes the biological activity of the human vascular endothelial growth factor (VEGF).

Which Firms Are Making The Biggest Impact In The Bevacizumab Biosimilars Market?

Major companies operating in the bevacizumab biosimilars market include Cipla Limited, Reliance lifesciences Pvt. Ltd., Fujifilm Kyowa Kirin Biologics Co. Ltd., Pfizer Inc., F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Mylan Inc., Daiichi Sankyo Company Limited, Beaconpharma Ltd., Innovent Biologics Inc., STADA Arzneimittel AG, Shanghai Henlius Biotech Inc., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Biocon Ltd., Intas Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC, Samsung Bioepis Co. Ltd., Celltrion Inc., Coherus BioSciences Inc., Hetero Drugs Ltd., Apotex Inc., BioXpress Therapeutics SA, mAbxience SA

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Which Geographic Regions Are Creating Strong Demand In The Bevacizumab Biosimilars Market?

North America was the largest region in the bevacizumab biosimilars market in 2024. The regions covered in the bevacizumab biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=10848&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model